Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects

详细信息    查看全文

• 作者：Bruna Scaggiante^a ; ¹ ; Rosella Farra^b ; ¹ ; Barbara Dapas^a ; Gabriele Baj^a ; Gabriele Pozzato^c ; Mario Grassi^b ; Fabrizio Zanconati^c ; Gabriele Grassi^a ; ^{ggrassi@units.it" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Liposome-delivery ; Cholesterol-delivery ; Aptamer ; eEF1A ; HCC
• 刊名：International Journal of Pharmaceutics
• 出版年：2016
• 出版时间：15 June 2016
• 年：2016
• 卷：506
• 期：1-2
• 页码：268-279
• 全文大小：1946 K

文摘

The high morbidity and mortality of hepatocellular carcinoma (HCC) is mostly due to the limited efficacy of the available therapeutic approaches. Here we explore the anti-HCC potential of an aptamer targeting the elongation factor 1A (eEF1A), a protein implicated in the promotion of HCC. As delivery methods, we have compared the effectiveness of cationic liposome and cholesterol-mediated approaches.

A75 nucleotide long aptamer containing GT repetition (GT75) was tested in three HCC cell lines, HepG2, HuH7 and JHH6. When delivered by liposomes, GT75 was able to effectively reducing HCC cells viability in a dose and time dependent fashion. Particular sensitive were JHH6 where increased apoptosis with no effects on cell cycle were observed. GT75 effect was likely due to the interference with eEF1A activity as neither the mRNA nor the protein levels were significantly affected. Notably, cholesterol-mediated delivery of GT75 abrogated its efficacy due to cellular mis-localization as proven by fluorescence and confocal microscopic analysis. Finally, liposome-mediated delivery of GT75 improved the therapeutic index of the anticancer drugs bortezomib and idarubicin.

In conclusion, liposome but not cholesterol-mediated delivery of GT75 resulted in an effective delivery of GT75, causing the impairment of the vitality of a panel of HCC derived cells.